Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 9/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30829782 | 1.00 | ERN1 (0.42) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL29654634 | 0.84 | ERN1 (0.43) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL8491593 | 0.84 | ERN1 (0.43) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL659120 | 0.84 | ERN1 (0.43) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL24034364 | 0.78 | MCL1 (0.33) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL16415856 | 0.78 | ERN1 (0.39) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL17295769 | 0.78 | TDP1 (0.42) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL745181 | 0.78 | ERN1 (0.46) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL16411961 | 0.78 | CA1 (0.41) | ERN1TDP1LMNATRIM24TRIM33 | |
| SCHEMBL30287124 | 0.77 | TDP1 (0.47) | ERN1TDP1MEN1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068354-A1 | SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-03 | — | — | WO | disclosed |
| CN-115232144-B | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN SCIENCES IRELAND UNLIMITED CO (US) | 2022-11-03 | — | — | US | disclosed |
| CN-115232144-A | Nitrogen-containing fused ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| EP-3455212-B1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | HEPTARES THERAPEUTICS LTD (GB) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021254416-A1 | INDANONE COMPOUND AND USE THEREOF | 贝达药业股份有限公司 | 2021-12-23 | — | — | WO | disclosed |
| WO-2021254417-A1 | BICYCLIC COMPOUND AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2021-12-23 | — | — | WO | disclosed |
| EP-3601257-B1 | AROMATIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-20210220356-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-22 | — | — | US | disclosed |
| US-20150031687-A1 | Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031687-A1 | Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031687-A1 | Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2014184328-A1 | 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-20 | — | — | WO | disclosed |
| US-20140343032-A1 | NOVEL 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2014-11-20 | — | — | US | disclosed |
| WO-2014037480-A1 | 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-13 | — | — | WO | disclosed |
| US-7560147-B2 | Liquid-crystal medium | MERCK PATENT GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| US-20080193681-A1 | Liquid-Crystal Medium | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1223209-B1 | Fluorinated fluorenes and use thereof in liquid crystal mixtures | CLARIANT INT LTD (CH) | 2004-03-03 | — | — | EP | disclosed |
| EP-1223209-A1 | Fluorinated fluorenes and use thereof in liquid crystal mixtures | CLARIANT INTERNATIONAL LTD. (CH) | 2002-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031687-A1 | Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | CYP2B6, HAVCR2, CYP2D6 | ERN1 2687/4885TDP1 1566/4885MEN1 4074/4885 |
| US-20210220356-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, TYMP, HAVCR2 | ERN1 2456/4885TDP1 1809/4885MEN1 4065/4885 |
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | ERN1 2346/4885TDP1 1753/4885MEN1 3958/4885 |
| US-20140343032-A1 | NOVEL 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP2D6, TPMT | ERN1 2462/4885TDP1 859/4885MEN1 3013/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | ERN1 2487/4885TDP1 1615/4885MEN1 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.